These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15584866)

  • 1. Janus kinase 3: a novel target for selective transplant immunosupression.
    Podder H; Kahan BD
    Expert Opin Ther Targets; 2004 Dec; 8(6):613-29. PubMed ID: 15584866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin.
    Stepkowski SM; Erwin-Cohen RA; Behbod F; Wang ME; Qu X; Tejpal N; Nagy ZS; Kahan BD; Kirken RA
    Blood; 2002 Jan; 99(2):680-9. PubMed ID: 11781254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PNU156804 inhibits Jak3 tyrosine kinase and rat heart allograft rejection.
    Stepkowski SM; Nagy ZS; Wang ME; Behbod F; Erwin-Cohen R; Kahan BD; Kirken RA
    Transplant Proc; 2001; 33(7-8):3272-3. PubMed ID: 11750401
    [No Abstract]   [Full Text] [Related]  

  • 4. Treating inflammation with the Janus kinase inhibitor CP-690,550.
    Vijayakrishnan L; Venkataramanan R; Gulati P
    Trends Pharmacol Sci; 2011 Jan; 32(1):25-34. PubMed ID: 21144599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK protein kinase inhibitors.
    Thompson JE
    Drug News Perspect; 2005 Jun; 18(5):305-10. PubMed ID: 16193102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant reduction of acute cardiac allograft rejection by selective janus kinase-1/3 inhibition using R507 and R545.
    Deuse T; Hua X; Taylor V; Stubbendorff M; Baluom M; Chen Y; Park G; Velden J; Streichert T; Reichenspurner H; Robbins RC; Schrepfer S
    Transplantation; 2012 Oct; 94(7):695-702. PubMed ID: 22971540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Jak3 tyrosine kinase by PNU156804 blocks rat heart allograft rejection.
    Wang M; Kirken R; Behbod F; Erwin-Cohen R; Stepkowski SM; Kahan BD
    Transplant Proc; 2001; 33(1-2):201. PubMed ID: 11266779
    [No Abstract]   [Full Text] [Related]  

  • 8. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders.
    West K
    Curr Opin Investig Drugs; 2009 May; 10(5):491-504. PubMed ID: 19431082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants.
    Borie DC; O'Shea JJ; Changelian PS
    Trends Mol Med; 2004 Nov; 10(11):532-41. PubMed ID: 15519279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities.
    Stepkowski SM; Kao J; Wang ME; Tejpal N; Podder H; Furian L; Dimmock J; Jha A; Das U; Kahan BD; Kirken RA
    J Immunol; 2005 Oct; 175(7):4236-46. PubMed ID: 16177063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts.
    Behbod F; Erwin-Cohen RA; Wang ME; Trawick BW; Qu X; Verani R; Kahan BD; Stepkowski SM; Kirken RA
    J Immunol; 2001 Mar; 166(6):3724-32. PubMed ID: 11238613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.
    Changelian PS; Flanagan ME; Ball DJ; Kent CR; Magnuson KS; Martin WH; Rizzuti BJ; Sawyer PS; Perry BD; Brissette WH; McCurdy SP; Kudlacz EM; Conklyn MJ; Elliott EA; Koslov ER; Fisher MB; Strelevitz TJ; Yoon K; Whipple DA; Sun J; Munchhof MJ; Doty JL; Casavant JM; Blumenkopf TA; Hines M; Brown MF; Lillie BM; Subramanyam C; Shang-Poa C; Milici AJ; Beckius GE; Moyer JD; Su C; Woodworth TG; Gaweco AS; Beals CR; Littman BH; Fisher DA; Smith JF; Zagouras P; Magna HA; Saltarelli MJ; Johnson KS; Nelms LF; Des Etages SG; Hayes LS; Kawabata TT; Finco-Kent D; Baker DL; Larson M; Si MS; Paniagua R; Higgins J; Holm B; Reitz B; Zhou YJ; Morris RE; O'Shea JJ; Borie DC
    Science; 2003 Oct; 302(5646):875-8. PubMed ID: 14593182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human lung myofibroblasts as effectors of the inflammatory process: the common receptor gamma chain is induced by Th2 cytokines, and CD40 ligand is induced by lipopolysaccharide, thrombin and TNF-alpha.
    Doucet C; Giron-Michel J; Canonica GW; Azzarone B
    Eur J Immunol; 2002 Sep; 32(9):2437-49. PubMed ID: 12207328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates.
    Borie DC; Changelian PS; Larson MJ; Si MS; Paniagua R; Higgins JP; Holm B; Campbell A; Lau M; Zhang S; Flores MG; Rousvoal G; Hawkins J; Ball DA; Kudlacz EM; Brissette WH; Elliott EA; Reitz BA; Morris RE
    Transplantation; 2005 Apr; 79(7):791-801. PubMed ID: 15818321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A receptor-independent, cell-based JAK activation assay for screening for JAK3-specific inhibitors.
    Oh K; Joo KM; Jung YS; Lee J; Kang H; Lee HY; Lee DS
    J Immunol Methods; 2010 Mar; 354(1-2):45-52. PubMed ID: 20138049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells.
    Kirken RA; Erwin RA; Wang L; Wang Y; Rui H; Farrar WL
    J Immunol; 2000 Nov; 165(9):5097-104. PubMed ID: 11046040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of early T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154.
    Säemann MD; Zeyda M; Diakos C; Szekeres A; Böhmig GA; Kelemen P; Parolini O; Stockinger H; Prieschl EE; Stulnig TM; Baumruker T; Zlabinger GJ
    Transplantation; 2003 Jun; 75(11):1864-72. PubMed ID: 12811247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.
    Sudbeck EA; Liu XP; Narla RK; Mahajan S; Ghosh S; Mao C; Uckun FM
    Clin Cancer Res; 1999 Jun; 5(6):1569-82. PubMed ID: 10389946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Jak3-regulated genes: DNA array analysis of concanavalin a-interleukin-2-activated chicken T cells treated with a specific jak3 inhibitor.
    Kampa D; Burnside J
    J Interferon Cytokine Res; 2002 Sep; 22(9):975-80. PubMed ID: 12396719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tofacitinib in kidney transplantation.
    Wojciechowski D; Vincenti F
    Expert Opin Investig Drugs; 2013 Sep; 22(9):1193-9. PubMed ID: 23841583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.